



HIFU treatment

September 9, 2008

We are pleased to announce that the Urology Times, a leading news source for urologists and patients recently featured an article on the high level of interest and promise surrounding HIFU treatment for patients with localized prostate cancer. Dr. Cary Robertson, a Duke University urologist and Principal Investigator for EDAP's Ablatherm-HIFU U.S. trials highlighted HIFU's potential as an important therapy in the future for the treatment of an aging male population.

If you would like to read the article please click on the link below:

<http://urologytimes.modernmedicine.com/urologytimes/article/articleDetail.jsp?id=534008>

Thank you for your continued support.

Yours sincerely,

Marc OCZACHOWSKI
Chief Executive Officer
EDAP-TMS

You are subscribed to EDAP TMS S.A. Investor Relations' e-mail alerts as **bconfort@edap-tms.com**.

To update your e-mail and alert preferences, please [click here](#).

To unsubscribe, please [click here](#).

EDAP TMS S.A.
4 rue du Dauphine
69120 Vaulx-en-Velin, France
France